Literature DB >> 1673344

Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy.

M L Wadenberg1, S Ahlenius.   

Abstract

The administration of the 5-HT1A agonist 8-OH-DPAT, 0.1 mg kg-1 sc-20 min, produced a moderate suppression of conditioned avoidance behavior (60% of controls) in the rat. This effect, however, was not seen after administration of higher doses, 0.4 and 1.6 mg kg-1 sc. The number of intertrial crosses were not affected by the lower dose but significantly increased by administration of the two higher doses of 8-OH-DPAT. The dopamine D2 receptor blocking agent raclopride, 0.05 mg kg-1, by itself did not suppress the avoidance behavior, but in combination with 8-OH-DPAT produced suppression of avoidance behavior (30% of controls) as well as intertrial crosses. Open field locomotor activity was suppressed by raclopride, 0.1 mg kg-1 sc, or by 8-OH-DPAT, 0.1 mg kg-1 sc. The combined treatment produced a further suppression of locomotor activity and a marked increase in "immobility" (stationary movements). Treadmill locomotion, however, was not affected by either compound by itself, whereas the combined treatment impaired treadmill performance. Suppression of treadmill performance by a higher dose of raclopride, 0.4 mg kg-1 sc, was not altered by the additional treatment with 8-OH-DPAT, 0.1 mg kg-1. In contrast to the additive effects of 8-OH-DPAT and raclopride on conditioned avoidance behavior, open field locomotion and treadmill performance, the catalepsy produced by raclopride, 16 mg kg-1 was completely antagonised by treatment with 8-OH-DPAT 0.1 mg kg-1. Taken together, the present findings demonstrate strong interactions between a 5-HT agonist and a DA D2 antagonist on some critical tests for antipsychotic-like actions and extrapyramidal motor effects in rats, and suggest new possibilities in the search for new antipsychotic drugs with higher clinical efficacy and less extrapyramidal side effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673344     DOI: 10.1007/bf01244451

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  26 in total

1.  The 5-HT 1A receptor agonist, 8-OH-DPAT, preferentially activates cell body 5-HT autoreceptors in rat brain in vivo.

Authors:  S Hjorth; T Magnusson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-11       Impact factor: 3.000

2.  Role of 5-HT in the action of some drugs affecting extrapyramidal system.

Authors:  W Gumulka; W Kostowski; A Czlonkowski
Journal:  Pharmacology       Date:  1973       Impact factor: 2.547

3.  Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs.

Authors:  B A McMillen; S M Scott; E A Davanzo
Journal:  J Pharm Pharmacol       Date:  1988-12       Impact factor: 3.765

4.  Effects of 5-HT and 8-OH-DPAT on forebrain monoamine synthesis after local application into the median and dorsal raphe nuclei of the rat.

Authors:  V Hillegaart; S Hjorth; S Ahlenius
Journal:  J Neural Transm Gen Sect       Date:  1990

5.  Serotonin--dopamine interactions in the nigrostriatal system.

Authors:  P C Waldmeier; A A Delini-Stula
Journal:  Eur J Pharmacol       Date:  1979-05-15       Impact factor: 4.432

6.  Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behaviour and catalepsy in rats: behavioural profile comparisons between raclopride, haloperidol and preclamol.

Authors:  V Hillegaart; S Ahlenius
Journal:  Pharmacol Toxicol       Date:  1987-05

7.  Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).

Authors:  J A Engel; S Hjorth; K Svensson; A Carlsson; S Liljequist
Journal:  Eur J Pharmacol       Date:  1984-10-15       Impact factor: 4.432

8.  Effects of (-)3-PPP on acquisition and retention of a conditioned avoidance response in the rat.

Authors:  S Ahlenius; T Archer; B Tandberg; V Hillegaart
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission.

Authors:  S Ahlenius; V Hillegaart
Journal:  Pharmacol Biochem Behav       Date:  1986-05       Impact factor: 3.533

10.  Suppression of conditioned avoidance by 8-OH-DPAT in the rat.

Authors:  M L Wadenberg; S Ahlenius
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

View more
  15 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat.

Authors:  M L Wadenberg
Journal:  J Neural Transm Gen Sect       Date:  1992

3.  In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.

Authors:  Marie-Bernadette Assié; Hélène Dominguez; Nathalie Consul-Denjean; Adrian Newman-Tancredi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-01       Impact factor: 3.000

4.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Authors:  R Depoortère; L Bardin; A L Auclair; M S Kleven; E Prinssen; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

Review 5.  Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.

Authors:  K D Alex; E A Pehek
Journal:  Pharmacol Ther       Date:  2006-10-17       Impact factor: 12.310

6.  Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.

Authors:  K Svensson; A Ekman; M F Piercey; W E Hoffmann; J T Lum; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

7.  Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation.

Authors:  Mark S Kleven; Marie-Bernadette Assié; Cristina Cosi; Catherine Barret-Grévoz; Adrian Newman-Tancredi
Journal:  Psychopharmacology (Berl)       Date:  2004-09-24       Impact factor: 4.530

8.  Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia.

Authors:  Xue Sun; Hong-yan Gou; Fei Li; Guan-yi Lu; Rui Song; Ri-fang Yang; Ning Wu; Rui-bin Su; Bin Cong; Jin Li
Journal:  Acta Pharmacol Sin       Date:  2016-01-18       Impact factor: 6.150

9.  Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine.

Authors:  M L Wadenberg; S Ahlenius; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 10.  5-HT1A receptor agonists: recent developments and controversial issues.

Authors:  J De Vry
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.